FDA Brief

Warning letters Drugs

FDA warning letter to

Jiangmen Shuizirun Sanitary Articles Co., Ltd.

High riskIssued Sep 23Posted Oct 13Center for Drug Evaluation and Research (CDER)

FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

What happened

FDA inspected the Jiangmen, Guangdong, China drug manufacturing facility from November 3 to 7, 2025. Investigators found that several OTC products labeled "sterile" are not sterilized and are not tested for sterility at release; one batch's own microbial worksheet reported aerobic bacteria counts within a non-sterile Chinese specification. FDA also found the company skipped identity and impurity testing on incoming components, relied on suppliers' certificates of analysis, and gave the same batch number to different products. After the company's November 23, 2025 response, FDA tried to reach the firm and its U.S. agent on February 3, 4 and 5, 2026 about a recall but got no reply, and placed all its drugs on Import Alert 66-40 on April 20, 2026.

What FDA found

  1. The company has no procedures to prevent microbial contamination in products it labels sterile, and it does not test those products for sterility before release.

    21 CFR 211.113(b)
  2. The company did not test each incoming shipment of each component for identity, purity, strength and quality, and did not verify that suppliers' certificates of analysis are reliable.

    21 CFR 211.84(d)(1), 211.84(d)(2), 211.110(c)
  3. The company did not run the USP identity test that screens high-risk components for dangerous impurities such as those that have caused lethal poisonings worldwide.

    21 CFR 211.84(d)(1), 211.84(d)(2)
  4. The quality control unit did not make sure production records were written when work was done, that processes were validated, that written procedures existed, that stability testing was done, and that finished products were tested.

    21 CFR 211.22, 211.100(a), 211.100(b), 211.166, 211.165(a), 211.165(b)
  5. The company gave the same batch number to different products with different active ingredients and routes of administration made on the same purchase order, so a batch's history cannot be traced.

    21 CFR 211.130(c)

What FDA wants

FDA tells the company to send a written response within 15 business days covering a plan to address the risks of sterile-labeled batches in U.S. distribution, including customer notifications and recalls or withdrawals, plus component testing, risk assessments and quality unit fixes. FDA also recommends hiring a qualified CGMP consultant to do a six-system audit before the firm seeks resolution of its compliance status.

Who should pay attention

  • brands and distributors that buy OTC drug products from this contract manufacturer
  • U.S. importers and retailers selling imported OTC drugs labeled sterile
  • companies that accept supplier certificates of analysis instead of testing incoming components

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk
  4. Neogen Corporation

    FDA found Neogen's HYCOAT animal drug contaminated and made under insanitary conditions after horse deaths.

    High risk